Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/14/2026

Tigecycline Dosing Recommendations

Standard Dosing for Approved Indications

  • The FDA-approved standard dosage for tigecycline is 100 mg IV loading dose followed by 50 mg IV every 12 hours, which is appropriate for patients with standard indications 1, 2
  • No dose adjustment is required for patients with renal impairment or those on continuous renal replacement therapy, as recommended by the FDA 1, 3

Higher Dosing for Severe Infections

  • For severe infections, particularly pulmonary infections, a high-dose regimen is recommended: 200 mg IV loading dose followed by 100 mg IV every 12 hours, with a cure rate of 85% compared to 69.6% with standard dosing 1, 2, 4
  • Higher dosing is particularly important for hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), with improved clinical outcomes 2, 4

Specific Clinical Scenarios

  • For carbapenem-resistant Enterobacterales (CRE) infections, tigecycline can be used in combination therapy with polymyxins or meropenem, with a recommended dose of 100 mg IV loading dose, then 50 mg IV q12h 5
  • For vancomycin-resistant Enterococci (VRE) complicated intra-abdominal infections, a recommended dose is 50 mg IV q12h after loading dose of 100 mg IV 5
  • For Acinetobacter baumannii infections, standard dosing is appropriate if MIC ≤1 mg/L, but high-dose regimen (200 mg loading followed by 100 mg q12h) is recommended for non-approved indications, with combination with another active agent recommended 3

Pharmacokinetic Considerations

  • Standard dosing achieves serum Cmax of only 0.87 mg/L, which may be insufficient for bloodstream infections, as noted by the Infectious Diseases Society of America 2
  • Tigecycline penetrates well into tissues but has low concentrations in endothelial lining fluid (0.01-0.02 mg/L), explaining lower efficacy in VAP with standard dosing, according to the American Thoracic Society 2

Important Clinical Caveats

  • Tigecycline should not be used as monotherapy for bacteremia due to poor outcomes with standard dosing, as recommended by the Infectious Diseases Society of America 2
  • For MDR organisms, combination therapy is generally preferred over tigecycline monotherapy, with a strength of evidence rated as high by the Society for Healthcare Epidemiology of America 3, 6

Tigecycline Dosing Recommendations for Multidrug-Resistant Organism Infections

Multidrug-Resistant Organism (MDRO) Infections

  • For carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, the Infectious Diseases Society of America recommends tigecycline 100 mg IV loading dose, then 50 mg IV q12h PLUS colistin PLUS sulbactam as triple combination therapy for at least 7 days, with a strength of evidence based on clinical trials 7
  • For carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections, the Infectious Diseases Society of America recommends the same dosing for 10-14 days, with a strength of evidence based on clinical trials 7
  • Tigecycline monotherapy is NOT recommended for pneumonia; combination therapy is essential, as stated by the Infectious Diseases Society of America, due to poor serum concentrations and documented treatment failures 7
  • The European Society of Clinical Microbiology and Infectious Diseases recommends using tigecycline only if MIC ≤2 mg/L, with a strength of evidence based on in vitro studies 7

Tigecycline Dosing Recommendations for Resistant Infections

Specific Clinical Scenarios

  • For Carbapenem-Resistant Enterobacterales (CRE) bloodstream infections, the Infectious Diseases Society of America recommends a 100 mg IV loading dose, then 50 mg IV every 12 hours in combination with colistin or meropenem (extended infusion) for 7-14 days 8
  • For Carbapenem-Resistant Enterobacterales (CRE) complicated intra-abdominal infections, the Infectious Diseases Society of America recommends a 100 mg IV loading dose, then 50 mg IV every 12 hours for 5-7 days 8
  • For Vancomycin-Resistant Enterococci (VRE) complicated intra-abdominal infections, the Infectious Diseases Society of America recommends a 100 mg IV loading dose, then 50 mg IV every 12 hours for 5-7 days 8
  • The Society for Healthcare Epidemiology of America suggests that for CRAB and severe CRE infections, combination therapy with another active agent is recommended over monotherapy, such as combining tigecycline with colistin or meropenem (extended infusion) 8

Tigecycline Post-Surgery Dosing Guidelines

Standard Dosing Regimens

  • The World Journal of Emergency Surgery recommends combining tigecycline with piperacillin/tazobactam 4.5 g every 6 hours for healthcare-associated intra-abdominal infections, with standard tigecycline dosing of 100 mg loading, then 50 mg every 12 hours 9

Specific Infection Scenarios

  • For healthcare-associated intra-abdominal infections, the World Journal of Emergency Surgery suggests using tigecycline as part of a carbapenem-sparing regimen, with a combination of piperacillin/tazobactam 4.5 g every 6 hours and standard tigecycline dosing of 100 mg loading, then 50 mg every 12 hours 9

Tigecycline Dosing Recommendations for Complicated Infections

Standard Dosing Regimen for Specific Infections

  • The World Journal of Emergency Surgery recommends a dose of 100 mg IV loading dose, then 50 mg every 12 hours for community-acquired intra-abdominal infections in patients at risk for ESBL-producing Enterobacteriaceae 10
  • The Journal of Microbiology, Immunology and Infection suggests that high-dose tigecycline (200 mg loading, then 100 mg every 12 hours) in combination therapy significantly reduced mortality (OR 0.44, 95% CI 0.30-0.66) compared to standard dosing for carbapenem-resistant Enterobacterales (CRE) infections 11

Pharmacokinetic Considerations for Tigecycline

  • The Journal of Microbiology, Immunology and Infection notes that tigecycline has excellent tissue penetration (Vd 7-9 L/kg) but low serum and urinary concentrations, limiting its use in bacteremia and urinary tract infections 12
  • For complicated intra-abdominal infections, the World Journal of Emergency Surgery recommends a carbapenem-sparing regimen: combine piperacillin/tazobactam 4.5 g every 6 hours with tigecycline 100 mg loading dose, then 50 mg every 12 hours 10
  • For carbapenem-resistant Enterobacterales (CRE) infections, the Journal of Microbiology, Immunology and Infection suggests considering a high-dose regimen (200 mg loading, then 100 mg every 12 hours) for bloodstream infections in combination with colistin or meropenem 11

Tigecycline Dosing and Safety Recommendations

Standard Adult Dosing

  • The U.S. FDA‑approved regimen for adults is a 100 mg intravenous loading dose followed by 50 mg intravenously every 12 hours; the loading dose is infused over 30–60 minutes. 13

Hepatic Impairment Adjustments

  • In patients with severe hepatic impairment (Child‑Pugh class C), the maintenance dose should be reduced by 50 % to 25 mg intravenously every 12 hours while retaining the 100 mg loading dose. This adjustment reflects the decrease in tigecycline clearance from ~30 L/h in healthy individuals to ~13.5 L/h in Child‑Pugh C patients. 13

Pediatric Considerations

  • Tigecycline is generally avoided in children because of increased mortality risk; however, when no alternative antibiotics exist, the following doses are recommended:
    • Ages 8–11 years: 1.2 mg/kg intravenously every 12 hours (maximum 50 mg per dose).
    • Ages 12–18 years: adult dosing (100 mg loading dose, then 50 mg every 12 hours).
  • Tigecycline is contraindicated in children younger than 8 years due to the risk of permanent tooth discoloration. 13

Monitoring Recommendations

  • Coagulation parameters should be monitored because tigecycline can prolong prothrombin time (PT) and activated partial thromboplastin time (aPTT). 13
  • Liver function tests should be checked periodically, as elevated hepatic enzymes have been reported during therapy. 13
  • Metabolic monitoring is advised; cases of hypoglycemia and hypoproteinemia have been observed in patients receiving tigecycline. 13

Contraindications

  • Known hypersensitivity to tigecycline or any tetracycline class antibiotic. 13
  • Pregnancy and breastfeeding are contraindicated because animal studies have demonstrated fetal harm. 13
  • Use in children under 8 years of age is prohibited due to the risk of permanent tooth discoloration. 13

Management of XDR Klebsiella Wound Infections Susceptible Only to Tigecycline

Therapeutic Strategy

  • High‑dose tigecycline (200 mg IV loading dose followed by 100 mg IV every 12 h) should be administered in combination with at least one other agent that shows any in‑vitro activity, even if marginal, rather than as monotherapy. 14

Guideline Recommendations (ESCMID 2022)

  • The ESCMID 2022 guidelines explicitly recommend combination therapy for severe carbapenem‑resistant Enterobacterales (CRE) infections when tigecycline is the only active old antibiotic. 15
  • For severe CRE infections susceptible only to polymyxins, aminoglycosides, tigecycline, or fosfomycin, the ESCMID guidelines advise using more than one drug that is active in‑vitro. 15
  • Aminoglycoside (e.g., amikacin 15–20 mg/kg IV q24 h or gentamicin 5–7 mg/kg IV q24 h) may be added when in‑vitro activity is demonstrated. 14
  • Fosfomycin (6–8 g IV every 8 h) can be used as a partner drug if susceptibility is confirmed. 14
  • High‑dose extended‑infusion meropenem (2 g IV over 3 h every 8 h) is an option when the isolate’s MIC is ≤ 8 mg/L. 15

Source‑Control Measures

  • Aggressive surgical debridement is essential for wound infections; repeat debridement should be performed as needed based on clinical response. 14

Avoidance of Suboptimal Therapy

  • Tigecycline monotherapy should be avoided because it is associated with significantly higher mortality compared with combination regimens. 15

Monitoring and Follow‑Up

  • Assess clinical response at 48–72 h; if no improvement is observed, consider adding a third active agent or reassessing source control. 14

Escalation and Alternative Therapies

  • Newer agents such as ceftazidime‑avibactam, meropenem‑vaborbactam, or cefiderocol may be considered if they become available and demonstrate activity against the isolate. 15
  • If treatment failure occurs despite adequate source control and combination therapy, repeat susceptibility testing is recommended to detect emerging resistance. 14

REFERENCES

← Return to Home